Genolution

Genolution Financial Leverage

The Financial Leverage (Equity Multiplier) of Genolution (225220.KQ) as of Oct 22, 2026 is 1.37. In the previous year, Financial Leverage (Equity Multiplier) was 1.33 — a change of 3.41% (higher).

Financial Leverage

1.37

YoY

3.41%

Last updated:

Financial Leverage (Equity Multiplier) of Genolution is 2025 1.37 . Financial Leverage (Equity Multiplier) of Genolution was 2024 1.33 . It decreases by 3.41% higher compared to the previous year.

The Genolution Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
3.78 KRW
Jan 1, 2019
5.09 KRW
Jan 1, 2020
1.37 KRW
Jan 1, 2021
1.15 KRW
Jan 1, 2022
1.21 KRW
Jan 1, 2023
1.30 KRW
Jan 1, 2024
1.33 KRW
Jan 1, 2025
1.37 KRW
The Genolution Financial Leverage history
YEARFinancial LeverageYoY
1.37+3.41%
1.33+2.21%
1.30+7.33%
1.21+4.65%
1.15-15.50%
1.37-73.14%
5.09+34.78%
3.78+221.08%
1.18+0.80%
1.17—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Financial Leverage (Equity Multiplier) of Genolution is 1.37 in 2025.

Financial Leverage (Equity Multiplier) of Genolution changed from 1.33 to 1.37, representing a 3.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Genolution since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Genolution with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Genolution

All Key Metrics — Genolution